Search
C4 Therapeutics Inc
CCCCAdd to Watchlist
3.310USD
+0.010+0.30%
Close 09-22 16:00（ET）
365.99MMarket Cap
LossP/E TTM
Pre-market 04:10 (ET)3.270USD-0.040-1.21%
Pre-market 04:10 (ET)About C4 Therapeutics Inc Company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
C4 Therapeutics Inc Profile
Ticker SymbolCCCC
Company nameC4 Therapeutics Inc
IPO dateOct 02, 2020
CEOHirsch (Andrew J)
Number of employees110
Security typeOrdinary Share
Fiscal year-endOct 02
Address490 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16172310700
Websitehttps://c4therapeutics.com/
Ticker SymbolCCCC
IPO dateOct 02, 2020
CEOHirsch (Andrew J)
Company Executives of C4 Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
363.16K
+67.35%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
363.16K
+67.35%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
324.75K
+66.80%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
324.75K
+66.80%
Dr. Kenneth C. (Ken) Anderson, M.D.
Dr. Kenneth C. (Ken) Anderson, M.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
--
--
Ms. Kendra R. Adams
Ms. Kendra R. Adams
Chief Financial Officer, Head - Corporate Affairs and Treasurer
Chief Financial Officer, Head - Corporate Affairs and Treasurer
--
--
Ms. Kelly A. Schick
Ms. Kelly A. Schick
Chief People Officer
Chief People Officer
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Dr. Leonard M. J. (Len) Reyno, M.D.
Dr. Leonard M. J. (Len) Reyno, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
363.16K
+67.35%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
363.16K
+67.35%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
324.75K
+66.80%
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
324.75K
+66.80%
Dr. Kenneth C. (Ken) Anderson, M.D.
Dr. Kenneth C. (Ken) Anderson, M.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
--
--
Ms. Kendra R. Adams
Ms. Kendra R. Adams
Chief Financial Officer, Head - Corporate Affairs and Treasurer
Chief Financial Officer, Head - Corporate Affairs and Treasurer
--
--
FAQs
Who are the top five shareholders of C4 Therapeutics Inc?
The top five shareholders of C4 Therapeutics Inc are: Dr. Paige Mahaney, Ph.D.
How many institutions hold shares of C4 Therapeutics Inc (CCCC)?
As of 2026Q1, 296 institutions hold shares of C4 Therapeutics Inc, with a combined market value of approximately 76.03M, accounting for 69.01% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -8776241.00.